HeartCare Medical (06609.HK) Announces NMPA Acceptance of Registration Application for Self-Expanding Intracranial Drug-Eluting Stent
January 22, 2026
Source: drugdu
29
On January 20, 2026, HeartCare Medical-B (06609.HK) issued an announcement stating that the registration application for its self-developed self-expanding intracranial drug-eluting stent has been formally accepted by the National Medical Products Administration (NMPA) of the People’s Republic of China.
Designed for the treatment of intracranial atherosclerotic stenosis, the stent is capable of supporting and reopening narrowed or obstructed lumens while effectively preventing in-stent restenosis.
The company stated that there are currently no similar products approved for marketing worldwide, and its research and development progress remains at a leading level within the industry. However, the announcement also noted that there is no guarantee the stent will ultimately be successfully commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the company's shares.
https://finance.eastmoney.com/a/202601213625547124.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Recombinant Zoster Vaccine (Shingles Vaccine) Receives Clinical Trial Approval Notice January 22, 2026
- Two drugs from Hengrui Medicine have received clinical trial approval January 22, 2026
- Subsidiary’s Drug Production License Changed January 22, 2026
- Sunshine Novo’s Small Nucleic Acid Drug IND Application Accepted; Innovative Drug Pipeline Enters Harvest Phase January 22, 2026
- Big news! Chia Tai Tianqing’s oral GLP-1 has been approved for clinical trials! Can its differentiated “biased” mechanism break through the red ocean market? January 22, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
